EA
TCRT icon

Emerald Acquisition’s Alaunos Therapeutics TCRT Stock Holding History

Emerald Acquisition’s Portfolio TCRT Stock Details TCRT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q3 		– Sell
-348
Closed -$286K – 3042
2016
Q2 		$286K Buy
+348
New +$379K ﹤0.01% 2646

Other funds holding TCRT

TS
Third Security Radford, Virginia $241M AUM 45.43% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
MVP
Miller Value Partners Sarasota, Florida $383M AUM 38.57% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
MP
MSD Partners New York $82.3M AUM 15.13% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
BGA
Belmont Global Advisors Dallas, Texas $106M AUM 2.89% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Emerald Acquisition's TCRT Position: Q3 2016 in Review

Emerald Acquisition sold out of Alaunos Therapeutics (TCRT) in Q3 2016, closing a stake of 348 shares — an estimated $286K sold.

Emerald Acquisition first reported a position in TCRT in Q2 2016 and held it in 1 quarter. The position peaked at $286K in Q2 2016. 140 funds tracked by Wall St. Rank hold TCRT as of Q3 2016.

  • Emerald Acquisition reported no remaining Alaunos Therapeutics position as of Q3 2016 after selling out during the quarter.
  • Emerald Acquisition sold 348 Alaunos Therapeutics shares in Q3 2016, an estimated $286K.
  • Emerald Acquisition first reported a position in Alaunos Therapeutics in Q2 2016 and held it in 1 quarter.
  • Emerald Acquisition's Alaunos Therapeutics position peaked at $286K in Q2 2016.
  • 140 funds tracked by Wall St. Rank held Alaunos Therapeutics as of Q3 2016.

Based on Emerald Acquisition's 13F filing for Q3 2016, filed 9 Nov 2016.